海外の治験の状況「1」での検索結果
251件の検索結果
- 進捗状況
- 試験名
- 対象疾患名
- 地域
- 登録日
Authorised
- Short-term effects of the substance dapagliflozin on the increase of blood sugar concentrations after meal and insulinsensitivity in type 1 diabetic patients.
- effects of Dapagliflozin on postprandial glucose excursion and fasting glucose homeostasis;Therapeutic area: Diseases [C] - Nutritional and Metabolic Diseases [C18]
- Austria
- 2014-08-04
Authorised
- Efficacy and Safety of Two Treatment Models in Subjects With Moderate to Severe Crohn's Disease (CALM)
- Crohn's disease MedDRA version: 17.0 Level: PT Classification code 10011401 Term: Crohn's disease System Organ Class: 10017947 - Gastrointestinal disorders ;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]
- Austria, Belgium, Czech Republic, France, Germany, Hungary, Italy, Netherlands, Spain, Sweden, United Kingdom, United States
- 2010-07-19
Authorised
- A Study of the Efficacy and Safety of Guselkumab in Participants with Moderately to Severely Active Crohn's Disease
- Moderately to Severely Active Crohn's Disease MedDRA version: 20.0 Level: PT Classification code 10011401 Term: Crohn's disease System Organ Class: 10017947 - Gastrointestinal disorders ;Therapeutic area: Diseases [C] - Immune System Diseases [C20]
- Australia, Austria, Belarus, Belgium, Bosnia and Herzegovina, Brazil, Canada, China, Colombia, Croatia, Czech Republic, France, Georgia, Germany, Greece, Hungary, Israel, Italy, Japan, Jordan, Korea, Republic of, Latvia, Lebanon, Lithuania, Macedonia, the former Yugoslav Republic of, Netherlands, New Zealand, Poland, Portugal, Russian Federation, Saudi Arabia, Serbia, Slovakia, South Africa, Spain, Taiwan, Tunisia, Turkey, Ukraine, United Kingdom, United States
- 2018-03-01
Authorised
- A Phase 1/2, Open-Label, Safety, Pharmacokinetic and Efficacy Study of Ascending Doses of Oral CK-101 in Patients with Advanced Solid Tumors
- EGFR Mutation-Positive Non-Small Cell Lung Cancer MedDRA version: 20.0 Level: PT Classification code 10061873 Term: Non-small cell lung cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) ;Therapeutic area: Diseases [C] - Cancer [C04]
- Australia, New Zealand, Poland, Russian Federation, Thailand, United States
- 2017-06-22
Authorised
- Blocking the inflammation-factor IL-1 as treatment for degenerative joint disease of the hands
- osteoarthritis of the hand;Therapeutic area: Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Therapeutic techniques [E02]
- Austria
- 2013-03-06
Authorised
- A clinical study testing the efficacy and safety of V565 in patients with Crohn's Disease
- Active Crohn's Disease MedDRA version: 20.0 Level: PT Classification code 10011401 Term: Crohn's disease System Organ Class: 10017947 - Gastrointestinal disorders ;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]
- Austria, Belgium, Canada, Czech Republic, Germany, Hungary, Netherlands, Poland, Slovakia, Ukraine, United Kingdom, United States
- 2016-11-02
Authorised
- A Phase 1/2 Study of an Anti-KIR Antibody in Combination With an Anti-PD1 Antibody in Patients With Advanced Solid Tumors
- Solid tumors MedDRA version: 19.0 Level: PT Classification code 10060121 Term: Squamous cell carcinoma of head and neck System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) ;Therapeutic area: Diseases [C] - Cancer [C04]
- Austria, Belgium, Canada, France, Germany, Italy, Netherlands, Spain, Switzerland, United Kingdom, United States
- 2016-10-06
Authorised
- A Study to evaluate the Effect and Safety of experimental drugs ABT-493/ABT-530 in adults with Chronic Hepatitis C Virus Genotype 1-6 Infection and Renal Impairment
- Chronic HCV Genotype 1-6 Infection MedDRA version: 19.0 Level: PT Classification code 10008912 Term: Chronic hepatitis C System Organ Class: 10021881 - Infections and infestations ;Therapeutic area: Diseases [C] - Virus Diseases [C02]
- Australia, Belgium, Canada, France, Greece, Italy, New Zealand, United Kingdom, United States
- 2015-11-03
Authorised
- Effectiveness and Safety of Sparsentan as treatment for Immunoglobulin A Nephropathy (IgAN)
- Immunoglobulin A Nephropathy (IgAN) MedDRA version: 20.0 Level: PT Classification code 10021263 Term: IgA nephropathy System Organ Class: 10038359 - Renal and urinary disorders ;Therapeutic area: Diseases [C] - Symptoms and general pathology [C23]
- Australia, Belgium, Croatia, Czech Republic, Estonia, France, Germany, Hong Kong, Hungary, Italy, Korea, Republic of, Lithuania, Malaysia, New Zealand, Poland, Portugal, Spain, Turkey, United Kingdom, United States
- 2018-07-30
Authorised
- Effectiveness and Safety of Sparsentan as treatment for Immunoglobulin A Nephropathy (IgAN)
- Immunoglobulin A Nephropathy (IgAN) MedDRA version: 20.0 Level: PT Classification code 10021263 Term: IgA nephropathy System Organ Class: 10038359 - Renal and urinary disorders ;Therapeutic area: Diseases [C] - Symptoms and general pathology [C23]
- Australia, Belgium, Croatia, Czech Republic, Estonia, France, Germany, Hong Kong, Italy, Korea, Republic of, Lithuania, New Zealand, Poland, Portugal, Spain, Taiwan, United Kingdom, United States
- 2018-07-17
